Brilinta regulatory update

AstraZeneca said that a committee of the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA) and the Society for Cardiovascular Angiography and Interventions (SCAI) updated guidelines for managing acute coronary syndromes (ACS) patients undergoing percutaneous coronary intervention (PCI) to include a recommendation for AstraZeneca's cardiovascular drug Brilinta ticagrelor. The reversible adenosine diphosphate (ADP) receptor (P2Y12) received a Class I recommendation for use as a "loading dose" in patients undergoing PCI who are receiving a bare-metal or drug-eluting stent. The committee also recommended that Brilinta be administered for >=12 months after PCI. The guidelines list Plavix clopidogrel and Effient prasugrel as options.

Brilinta is approved in the U.S. to reduce the rate of thrombotic cardiovascular events in ACS patients. It is approved as Brilique in the EU to prevent atherothrombotic events in ACS patients. ...